Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: May 25, 2011

Premium

RainDance Technologies said yesterday that it has appointed Andy Watson as vice president and chief marketing officer. Watson will lead RainDance's global marketing and strategy efforts to grow the current commercial targeted sequencing business and prepare the market for the launch of its digital PCR and single-cell analysis products.

Watson joins RainDance from Life Technologies, where he was most recently vice president of SOLiD sequencing product management. Previously, he led Applied Biosystems' (now part of Life Technologies) capillary electrophoresis sequencing business, including instruments, reagents, and software.

Before joining Applied Biosystems, Watson helped found Quantum Dot (acquired by Invitrogen and now part of Life Technologies), where he held executive technical and business management roles. He also led the development of technologies and software for large-scale DNA analysis at Sequana Therapeutics (acquired by Celera); and the Wellcome Trust Sanger Institute.

Watson holds MEng, MA, and BA degrees from King's College, Cambridge University.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.